Q4 2025 · 13F-HR
KVP Capital Advisors, LPholdings as filed
Filed 2026-02-18 · accession 0001104659-26-016901
$103.3M
Reported value
27
Positions
2025-12-31
Period end
The Brief · KVP Capital Advisors, LP · Q4 2025
AI · grounded in 13F
KVP Capital Advisors, LP established a new position in Terns Pharmaceuticals Inc 430 valued at $17.78M. The fund also initiated new stakes in Praxis Precision Medicines I PRAX for $12.64M and Axsome Therapeutics Inc AXSM for $6.61M. Other new additions include Jazz Pharmaceuticals PLC JAZZ, Whitehawk Therapeutics Inc WHWK, and Trevi Therapeutics Inc TRVI.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $17.8M | 17.2% | 440,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $12.6M | 12.2% | 42,900 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $6.6M | 6.40% | 36,200 | Common | SOLE |
| G50871905 | JAZZ | JAZZ PHARMACEUTICALS PLC | $5.3M | 5.10% | 31,000 | CALL | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $5.2M | 5.07% | 2,165,997 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $5.2M | 5.02% | 414,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $5.0M | 4.80% | 28,497 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $4.6M | 4.48% | 53,000 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $4.6M | 4.48% | 58,250 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $3.8M | 3.71% | 121,524 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $3.6M | 3.53% | 605,280 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $3.5M | 3.36% | 91,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $3.3M | 3.19% | 133,000 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $3.0M | 2.88% | 17,500 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $2.8M | 2.67% | 59,700 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $2.3M | 2.24% | 4,750 | Common | SOLE |
| 004468500 | ACHV | ACHIEVE LIFE SCIENCES INC | $2.3M | 2.22% | 462,355 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $2.2M | 2.12% | 27,500 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $2.0M | 1.92% | 45,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $1.7M | 1.60% | 32,700 | Common | SOLE |
| 359616909 | FULC | FULCRUM THERAPEUTICS INC | $1.3M | 1.21% | 110,900 | CALL | SOLE |
| 45258H106 | IMMX | IMMIX BIOPHARMA INC | $1.2M | 1.17% | 230,423 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $1.1M | 1.10% | 26,900 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $1.1M | 1.07% | 505,431 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $565,500 | 0.55% | 50,000 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $398,960 | 0.39% | 4,000 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $290,370 | 0.28% | 500,551 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.